421 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first quarter of 2024 …
Research and development
General and administrative
Total operating costs and expenses
Income from operations
Gain from short-term investments
Interest
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
, compared with $8.5 million for the same period in 2022. Research and development expenses were $5.5 million for the fourth quarter of 2023, compared … . Amortization of intangibles was $33.7 million for 2023, compared with $34.2 million for 2022. Research and development expenses were $24.5 million
8-K/A
EX-99.1
yvita
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
2j0wv2wa
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
aqq xwk87pdxkd
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
xuthqas48bjj6ll
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
ksg6i
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
8-K
EX-99.1
ftk rz8igsasdr151krv
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
8-K
EX-99.1
mos54f20df8b i53
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
425
EX-99.1
ceqm 3z1xk8vbjejdms
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
ri1e5
21 Jun 22
Regulation FD Disclosure
6:19am
425
qtv2q 0hgnpcq4xjhs4t
5 May 22
Business combination disclosure
7:30am